Healthcare, Pharmaceuticals & Life Sciences in Southeast Europe

Sector Overview

The healthcare, pharmaceuticals, and life sciences industry in Southeast Europe is expanding rapidly, driven by rising private healthcare expenditure, modernizing public health systems, and significant foreign investment into generic drug manufacturing, biopharmaceuticals, clinical trials, and medical devices.

The region offers a rare combination of world-class medical universities, experienced clinical researchers, and cost-competitive manufacturing facilities fully compliant with European Medicines Agency standards.

Major generic drug producers and global biopharmaceutical giants are scaling up local production capacity to supply European healthcare networks seeking to avoid global pharmaceutical supply chain disruptions.

Key sector challenges include demographic aging, rising public healthcare expenditure constraints, and brain drain of qualified healthcare professionals migrating to Western Europe.

Stakeholders, Key Regional Investments & Projects

The healthcare and life sciences ecosystem includes global pharmaceutical multinationals, specialized contract research organizations, private healthcare providers, and domestic generic producers.

Global pharmaceutical leaders operating regional manufacturing and clinical research facilities include Roche, Novartis, Sandoz, Pfizer, Teva, and Zentiva.

Leading native generic drug and specialty champions include Krka in Slovenia, Alkaloid in North Macedonia, Pharmathen and ELPEN in Greece, and Zentiva Romania. Supporting this sector is a specialized supply chain of cold-chain logistics providers, clinical trial management agencies, and high-tech medical equipment distributors.

Major pharmaceutical production expansions demonstrate the region’s role in global medicine supply chains. In Slovenia, Sandoz committed over $490 million to build a new biosimilar production hub in Lendava and a development center in Ljubljana, while Novartis expanded its Mengeš site with a €111 million BioCampus and a specialized viral vector facility for cell and gene therapies. In Novo Mesto, Slovenia, Krka operates automated pharmaceutical synthesis complexes exporting generic prescription drugs worldwide. In Skopje, North Macedonia, Alkaloid continues to scale its chemical and pharmaceutical production centers for European export. In Greece, ELPEN Group executed a €155 million investment strategy establishing new production units in Keratea, an oncology plant in Tripoli, and the Athens LifeTech Park in Spata, while Pharmathen expanded its API capabilities by acquiring CBL Patras to support long-acting injectables.

Private hospital network investments, clinical trial centers, and biotech research hubs are expanding specialized healthcare access. In Belgrade, Serbia, the state-backed €450+ million BIO4 Campus represents the region’s largest single life-sciences investment, integrating university faculties, research institutes, and international commercial R&D labs dedicated to biomedicine, AI, and biotechnology. Simultaneously, private equity investors continue to scale Belgrade’s private hospital systems to meet demand for oncology and elective procedures. In Bucharest, Romania, private operators like Regina Maria and MedLife lead capital deployment into modern multi-specialty hospitals and automated diagnostic laboratories. In Zagreb, Croatia, specialized orthopedic and cardiovascular clinics attract patients from across Central Europe.

Contract manufacturing and specialized engineering complete the regional health ecosystem. In Bucharest, Romania, Zentiva operates major active pharmaceutical ingredient and finished-dosage manufacturing plants supplying European health networks. In Sofia, Bulgaria, international contract research organizations manage multi-center clinical trial hubs leveraging a strong network of university teaching hospitals. In Tirana, Albania, joint public-private investments are modernizing regional hospital diagnostic infrastructure and laboratory networks. Finally, in Sarajevo, Bosnia and Herzegovina, domestic pharmaceutical manufacturers are expanding solid-dosage production capacity targeted at regional export markets.

Macro Growth Drivers & Future Outlook

European nearshoring initiatives and legislative frameworks like the EU Critical Medicines Act provide strong structural incentives for pharmaceutical firms to expand manufacturing and R&D capacity in Southeast Europe.

At the same time, shifting regional demographics and increasing wealth are accelerating private demand for modern diagnostic services, preventive healthcare, and specialized treatments.

The availability of highly qualified medical professionals and EMA-compliant production plants provides a clear competitive edge.

To sustain growth, regional governments must implement retention policies for medical talent and streamline public procurement and reimbursement processes for innovative therapies.